Semaglutide
Semaglutide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Overweight、Obesity、Type 2 Diabetes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
13 项
已进入 III/IV 期
19 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Novo Nordisk A/S
- Nordsjaellands Hospital
- University College Dublin
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- University Health Network, Toronto
- McMaster University
- University of Texas Southwestern Medical Center
- Karolinska Institutet
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
丹麦、爱尔兰、加拿大、美国、瑞典、Pakistan、意大利、中国、Algeria、Slovenia、Israel、澳大利亚
正在招募患者的 Semaglutide 研究
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
IV 期招募中丹麦NCT07136714Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
不适用招募中爱尔兰NCT04174755Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
II 期 / III 期招募中加拿大NCT07891156The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
II 期招募中加拿大NCT05938712Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
IV 期招募中加拿大NCT07900074IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
不适用招募中美国NCT07361874The Evira Study: Additional Support During Obesity Treatment
不适用招募中瑞典NCT06836284Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
IV 期招募中PakistanNCT07513168GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
IV 期招募中意大利NCT07314684Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
不适用招募中中国NCT07732738Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
IV 期招募中美国NCT07058155OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
不适用招募中AlgeriaNCT07779343Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
II 期 / III 期招募中丹麦NCT06423599Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
IV 期招募中SloveniaNCT06613854Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
IV 期招募中美国NCT07178145Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
IV 期招募中美国NCT07213466A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
IV 期招募中美国NCT07728383Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
II 期招募中美国加拿大NCT05822609Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
I 期 / II 期招募中IsraelNCT07563699The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
I 期招募中丹麦NCT07010432Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
IV 期招募中美国NCT06706284Protein Supplementation Intervention on Body Weight
不适用招募中中国NCT06989203A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
II 期招募中美国澳大利亚德国HungaryNCT07668388Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
III 期招募中美国NCT07817251
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。